About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.

The Natural History of Familial Dysautonomia

Clinicaltrials.gov identifier NCT03920774

Recruitment Status Recruiting

First Posted April 19, 2019

Last update posted May 13, 2020

Study Description

Brief summary:

The study will collect clinical information from patients with FD and allow them to give blood to help develop biological markers of the disease to aid diagnosis and treatment. This is a non-invasive, non-interventional, observation study that poses only minimal risk for participants. The study will document the clinical features of patients with FD overtime by storing their routine clinical test results in a central database. The study will involve collaborators at other specialist clinics around the world who follow/evaluate patients with FD annually. Providing blood for future use is optional.

  • Condition or Disease:Familial Dysautonomia (Riley-Day Syndrome)
    Hereditary Sensory and Autonomic Neuropathies
    Hereditary Sensory and Autonomic Neuropathy 3
  • Intervention/Treatment:
  • Phase: N/A
Detailed Description

Define the phenotypic characteristics, severity and clinical evolution of FD on a patient-by patient basis. Investigators will enroll patients with FD in a multi-center observational natural history study to evaluate their biochemical, neurological and autonomic phenotype. Investigators will follow patients to systematically study the onset and scaled severity of all clinical problems. Investigators will define progression rates of patients outside of a clinical trial to distinguish between static and progressive features, a challenge in congenital neuropathies. Investigators will continue banking blood to look for ways to monitor the disease phenotypes. Biomarkers that quantify renal, cardiovascular, respiratory, skeletal and cognitive aspects of the disease will be evaluated. This information is relevant when monitoring toxicity to drugs in clinical trials. Detailed clinical follow-up of patients with FD will allow investigators to determine when standard of care therapies (e.g., non-invasive ventilation, gastrostomy feedings) should be initiated and how these impact survival outcomes. Specific Aim 2: Develop ways to measure progressive neurological deficits as outcome measures for future clinical trials. Investigators will test the hypothesis that worsening gait ataxia and progressive visual loss are caused by ongoing neuronal degeneration. Investigators will develop precise outcome measures based on these deficits to test the efficacy of new treatments. Investigators will prospectively evaluate longitudinal changes in the retinal structure (with optical coherence tomography) and visual function in a cohort of patients with FD. Investigators will determine the extent and severity of retinal abnormalities in all patients and how they change overtime. Investigators will establish whether structural abnormalities in the retina are correlated with disease severity and look for functional correlates as measured by visual acuity and color discrimination. Following the recent discovery that gait ataxia in patients with FD is the result of sensory deficits, investigators will perform quantitative assessments of passive joint angle matching at the knee to measure proprioceptive acuity. Investigators will determine how these measures change overtime as well as their impact on daily function and quality of life. An organized, multi-site natural history study of patients with FD will enable investigators to define disease-specific outcomes for testing new therapies, a major breakthrough for these patients. The study also offers a unique opportunity to understand better how the brain develops when devoid of crucial sensory inputs.

Study Design
  • Study Type: Observational
  • Estimated Enrollment: 400 participants
  • Observational Model: Cohort
  • Time Perspective: Prospective
  • Official Title: Natural History of Familial Dysautonomia
  • Actual Study Start Date: February 2017
  • Estimated Primary Completion Date: February 2022
  • Estimated Study Completion Date: December 2022
Outcome Measures
  • Primary Outcome Measures: 1. 1. To create a database of familial dysautonomia disorder that will serve as a phenotypic core [ Time Frame: 5 years ]
    Investigators will create an enrollment database of patients with familial dysautonomia. All patients will have standardized phenotypic evaluations that will combine clinical, physiological and biochemical strategies to characterize complex autonomic phenotypes, both known and still undiscovered.
  • Secondary Outcome Measures: 1. To define the natural history of visual function and identify predictive biomarkers of disease progression and severity. [ Time Frame: 5 years ]
    Investigators will map the natural history of visual function including retinal structure and visual acuity and test the hypothesis that worsening visual loss is caused by ongoing neuronal degeneration.
  • 2. To define the natural history of gait ataxia and identify predictive biomarkers of disease progression and severity [ Time Frame: 5 years ]
    Investigators will map the natural history of gait ataxia and test the hypothesis that progressive ataxia is correlated with increasing loss of proprioceptive acuity caused by ongoing death of sensory neurons.
  • Biospecimen Retention: Samples With DNA

    optional blood sample

Eligibility Criteria
  • Ages Eligible for Study: 4 Years and older (Child, Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
  • Sampling Method: Non-Probability Sample
  • Study Population: This study will involve as many as 400 human subjects. Registered patients range from 3 months to 66-years in age. This is a natural history study that will collect information obtained as standard of care from patients with FD. The study will involve children as it is a genetic disease with onset at birth. Adult patients will also be enrolled.
Criteria

Inclusion Criteria:

- Patients of any age with a diagnosis of familial dysautonomia (FD) with molecular
confirmation of the IKBKAP mutation.

- Ability to provide informed consent (or assent) and comply with the study protocol

Exclusion Criteria:

- Subjects that do not wish to be a part of the study.

Contacts and Locations
Contacts

Contact: Maria Cotrina, PhD 212 263 7225 Maria.Cotrina@nyulangone.org

Contact: Lucy Norcliffe-Kaufmann, PhD 212 263 7225 Lucy.Norcliffe-Kaufmann@nyulangone.org

Locations

United States, New York
Dysautonomia Center - School of Medicine -NYU Langone Medical Center
New York

Israel, Ramat Gan
Sheba Medical Center - Safra Children's Hospital
Tel HaShomer

Sponsors and Collaborators

NYU Langone Health

Investigators

Principal Investigator: Lucy Norcliffe-Kaufmann, PHD NYU Langone Health

More Information
  • Responsible Party: NYU Langone Health
  • ClinicalTrials.gov Identifier: NCT03920774 History of Changes
  • Other Study ID Numbers: i16-01774
  • First Posted: April 19, 2019 Key Record Dates
  • Last Update Posted: May 13, 2020
  • Last Verified: May 2020
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Primary Dysautonomias
    Autonomic Nervous System Diseases
    Dysautonomia, Familial
    Hereditary Sensory and Autonomic Neuropathies
    Nervous System Diseases